ABSTRACT In patients with atherosclerotic coronary artery disease, cigarette smoking increases myocardial oxygen demand but may cause an inappropriate decrease in coronary blood flow and myocardial oxgyen supply. This study was performed to explore the mechanism of smoking-induced coronary vasoconstriction and, specifically, to determine if smoking causes an ct-adrenergically mediated increase in coronary artery tone. In 36 chronic smokers with coronary artery disease (27 men and nine women, 50 9 [mean + SD] years old), heart rate-systolic arterial pressure double product and coronary sinus blood flow (by thermodilution) were measured before and during smoking both before and after (1) normal saline (n = 5, control subjects), (2) an at-adrenergic-blocking agent, phentolamine, 5 mg (n 15), (3) a /3-adrenergic-blocking agent, propranolol, 0.1 mg/kg (n = 12), or (4) sodium nitroprusside, 0.4 to 0.8 g.g/kg/min, given in a dose sufficient to diminish systolic arterial pressure by 15% (n 4). During the initial smoking period, rate-pressure product increased and coronary sinus blood flow was unchanged by smoking in all groups. After 30 to 75 min, saline, phentolamine, propranolol, or sodium nitroprusside was given, and measurements were repeated. In the control subjects, rate-pressure product and coronary sinus blood flow responded in a similar manner to that observed previously. In those receiving phentolamine, rate-pressure product was unchanged, but coronary sinus blood flow rose substantially with smoking (percent change + 2 + 15% during the first smoking period [before phentolamine] and +32 + 17% during the second smoking period [after phentolamine]; p < .01). In the 12 patients who received propranolol, rate-pressure product was unchanged, but coronary sinus blood flow fell with smoking (percent change + 5 + 14% during the first smoking period [before propranolol], -12 + 5% during the second smoking period [after propranolol]; p < .01). In those who received sodium nitroprusside, rate-pressure product fell slightly, and coronary sinus blood flow responded in a similar manner to that observed previously. Thus, smoking-induced coronary vasoconstriction is due to an ca-adrenergically mediated increase in coronary artery tone.
PATHOPHYSIOLOGY AND NATURAL HISTORY-CORONARY ARTERY DISEASE ing-induced coronary vasoconstriction is mediated by a-adrenergic stimulation. Materials In four patients receiving propranolol, the arterialcoronary sinus oxygen content difference was measured before and during the second smoking period (after administration of propranolol). In these patients, baseline coronary sinus blood flow was 116 + 37 ml/min, and the arterial-coronary sinus oxygen content differences was 9.7 + 0.9 ml/dl. During smoking, coronary sinus blood flow fell (103 + 34 ml/min, p < .05) and the arterial-coronary sinus oxygen content difference widened (10.5 ± 0.4 ml/dl, p < .05).
In the four patients who received sodium nitroprusside, the pacing rate was 82 ± 9 (range 70 to 92) beats/min. Systolic arterial pressure was 128 ± 22 mm Hg during baseline 1 and 108 ± 18 mm Hg during baseline 2 (p < .05). In these patients, systolic pressure rose with smoking before nitroprusside (134 ± 22 mm Hg, p < .05 in comparison with baseline 1), but did not change with smoking after nitroprusside (1 13 ± 12 mm Hg, NS in comparison with baseline 2). Since heart rate was held constant, heart rate-systolic arterial pressure double product behaved in a manner similar to systolic pressure. Coronary sinus blood flow during the two baseline periods was similar (1 12 ± 15 ml/min during baseline 1 and 114 ± 19 ml/min during baseline 2, NS). During the first smoking period, it was not altered significantly (1 16 + 21 ml/min); the percent change in flow averaged +4 ± 6%. During the second smoking period, coronary sinus blood flow behaved similarly (1 19 + 26 ml/min), and the percent change was + 4 ± 5% (NS in comparison with the first smoking period).
Discussion
In patients with atherosclerotic coronary artery dis- #2 PROPRANOLOL FIGURE 1. The percent change in coronary sinus blood flow induced by smoking before (# 1) and after (#2) normal saline (n = 5, control subjects), 5 mg phentolamine (n = 15) or 0.1 mg/kg propranolol (n = 12). In the control subjects. the percent change in coronary sinus blood flow was similar during the two smoking periods. In contrast, it rose after phentolamine and fell after propranolol. *p < .0l in comparison with the values obtained during, the first smoking period. 1). Furthermore, such inappropriate coronary vasoconstriction is prevented by phentolamine, an a-adrenergic-blocking agent, and is potentiated by propranolol, a 83-adrenergic-blocking agent. Thus, cigarette smoking limits or abolishes the coronary dilatation that should occur in response to increased myocardial oxygen demand because of an a-adrenergic augmentation of coronary artery tone.
Evidence for a-adrenergically mediated coronary vasoconstriction with other provocative maneuvers. In patients with atherosclerotic coronary artery disease exposure to cold increases myocardial oxygen demand but induces a concomitant increase in coronary vascular resistance. This inappropriate increase in coronary artery tone is prevented by phentolamine, an a-adrenergicblocking agent,10 and is potentiated by propranolol, a B-adrenergic-blocking agent.' Thus, coronary artery tone appears to be sensitive and responsive to alterations in az-,8-adrenergic "balance" in some patients with atherosclerotic coronary artery disease. Cryer et al. 1 have shown that the plasma concentrations of norepinephrine and epinephrine rise during cigarette smoking and that the peripheral hemodynamic effects of smoking are abolished with combinedca-and /3-adrenergic blockade. Others have shown that nonselective ,e-adrenergic blockade with propranolol augments the smoking-induced increase in peripheral vascular tone.' -5 Our data demonstrate that smokinginduced coronary vasoconstriction is prevented by aadrenergic blockade and is exaggerated by ,3-adrener-666 gic blockade. In short, the response of the coronary vasculature to smoking is similar to that previously observed with exposure to cold. supporting the premise that phentolamine exerts its coronary vasodilative effect as an at-adrenergic blocker, not as a nonspecific vasodilator. However, our data do not allow us to determine if these smokinginduced alterations in coronary tone are due to (1) a direct stimulation of coronary arterial adrenergic receptors or (2) a generalized increase in circulating catecholamines.
Other mechanisms by which smoking may induce coronary vasoconstriction. Apart from an increase in aadrenergic tone, smoking may induce coronary vasoconstriction in other ways. First, it stimulates the secretion of arginine vasopressin, a powerful constrictor of systemic and coronary arteries. 16 However, the alterations in coronary blood flow caused by smoking do not appear to be related to the smoking-induced changes in plasma arginine vasopressini. Second, smoking alters platelet reactivity and may induce the release of the potent vasoconstrictor, thromboxane A2.l. 1 ' At the same time, it may diminish coronary endothelial production and release of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation. 19' 20 However, smoking induces no change in the concentrations of thromboxane B, or 6-keto-PGF a (the stable metabolites of thromboxane A, and prostacyclin, respectively) in coronary sinus blood.2 Although these studies show no relationship between smoking-induced coronary vasoconstriction and plasma concentrations of arginine vasopressin, thromboxane A2, or prostacyclin, it is possible that such vasoconstriction is multifactorial in cause and that, in some patients, the effect of smoking on the production and release of these substances may alter coronary artery tone.
Limitations of the study. In this study, we measured total coronary sinus blood flow during smoking but did not assess its effects on regional myocardial blood flow. As a result, we are unable to define the precise anatomic location of the smoking-induced a-adrenergically mediated increase in coronary artery tone. Further studies are needed to determine if these alterations in coronary blood flow and resistance occur at sites of atherosclerotic narrowing, in arterial segments that are free of disease, or both.
Clinical implications. In long-term smokers with atherosclerotic coronary artery disease, cigarette smoking augments myocardial oxygen demand but may reduce coronary blood flow and myocardial oxygen supply. Since this coronary vasoconstriction is abolished by a-adrenergic blockade with phentolamine and is potentiated by f3-adrenergic blockade with propranolol, it appears due to a primary a-adrenergically mediated increase in coronary artery tone.
